Stocks-ALNY-Alnylam Pharmaceuticals Inc

ALNY Alnylam Pharmaceuticals Inc

209.20 -3.52 (-1.65%)
Invest
Invest
-4.54% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
25.74B
Day’s Range
207.78
-
216.38
52W Range
117.27
-
236.22
Volume (3M)
954.77K
Price-Earnings Ratio
-
Revenue
960.92M

Alnylam Pharmaceuticals Inc Latest News

View All
Top Discussions

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc is a speciality biopharmaceutical company based in Cambridge, Massachusetts. The firm was founded by a group of dedicated scientists and was incorporated in Delaware in 2002. It has offices around the globe, including the UK, Germany, Italy, Sweden, Japan and Brazil. The focus of Alnylam’s research is the science of RNAi (RNA interference) and to transform the lives of patients suffering from chronic diseases. The company went public in May 2004 and is traded on the NASDAQ, under the ticker ALNY. As of August 2020, the ALNY stock chart showed a 52-week high of $167.33 and a 52-week low of $73.32. In 2020, the firm employed over 1,400 full-time members of staff. Alnylam revenue for the 12 months ending the 30th June 2020 showed a year-over-year increase of 241.39%. Alnylam Pharmaceuticals continues to grow and innovate with a strong focus on research and development. The company focuses on continual innovation in order to improve the lives of individuals living with diseases which only have limited treatment options. Diversify your investments today with this medical innovator, and add ALNY stock to your eToro portfolio.
1.6K
Employees
Cambridge, Massachusetts, US
HQ
2002
Founded
Yvonne L. Greenstreet, MD, MBA
CEO
Show More

Upcoming Earnings

9
FEB
REPORTS
Alnylam Pharmaceuticals Inc Q4 2022 earnings report is expected to be released before market open

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
52
Medium
Industry 
Avg. 47 
42
Environment
53
Social
56
Governance

People Also Bought